Bladder Cancer

What is Bladder Cancer?

The bladder, a part of the urinary system, is a hollow organ in the pelvis with the primary function of storing and then eliminating urine that drains into it from the kidney. Cancer of the bladder develops when abnormal cells in the bladder start to grow out of control. Rutgers Cancer Institute expert explains what you need to know.

MD Anderson and UroGen Pharma announce strategic research collaboration to advance investigational treatment for high-grade bladder cancer

MD Anderson and UroGen today announced a strategic three-year collaboration agreement to advance combination immunotherapy, delivered directly into the bladder, for the treatment of high-grade non-muscle invasive bladder cancer. The collaboration will work through MD Anderson’s immunotherapy platform to design pre-clinical and clinical studies.

Multiple Sclerosis May Not Put You at Risk for Breast, Colorectal Cancers

People with multiple sclerosis (MS) may not be at higher risk of developing two of the three cancers that occur most commonly in people with MS, breast and colorectal cancer, than people who don’t have the disease, according to a new study published in the November 25, 2020, online issue of Neurology®, the medical journal of the American Academy of Neurology. However, the study did find that people with MS had a higher incidence of bladder cancer.

Protect Your Bladder: Quit Smoking

Your bladder probably isn’t your favorite topic of conversation, but knowing when to talk to your doctor about it is crucial to your health. If you experience frequent and/or painful urination, or you notice blood in your urine, telling your primary care provider is the first step to diagnosing a problem and finding the right care. More often than not, these symptoms are caused by non-life-threatening conditions like urinary tract infection, overactive bladder or, in men, an enlarged prostate. But they also could be symptoms of bladder cancer, the sixth most common form of cancer in the United States.

Phase III Trial Shows Avelumab an Immunotherapy Treatment for Advanced Urothelial Cancer Prolongs Overall Survival

During a plenary session of the 2020 American Society of Clinical Oncology (ASCO) Virtual Scientific Program, findings will be presented from the global phase III JAVELIN Bladder 100 randomized study conducted by investigators from Seattle Cancer Care Alliance, Fred Hutchinson Cancer Research Center and University of Washington Medicine along with several other research centers. The results demonstrated significantly prolonged overall survival of patients with locally advanced (unresectable) or metastatic urothelial cancer when treated with first-line immunotherapy avelumab plus best supportive care (BSC) compared to BSC alone (following disease control on induction chemotherapy).

Combination of Chemo and Immunotherapy Is Shown to Work Against Metastatic Bladder Cancer

A clinical trial led by Mount Sinai researchers has showed for the first time that combining chemotherapy and immunotherapy can slow down metastatic bladder cancer. The trial also showed that immunotherapy alone may be an option for a subset of patients with metastatic bladder cancer if their tumor expresses a high level of a protein called PD-L1 according to the study, published in The Lancet in May.

E-cigarette users had substances linked to bladder cancer in urine

In the review published in the journal European Urology Oncology, researchers compiled the results of 22 different studies that analyzed the urine of people who used e-cigarettes or other tobacco products, including cigarettes, to check for evidence of cancer-linked compounds or biomarkers of those compounds. They found six biomarkers or compounds with a strong link to bladder cancer.